Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Newbury Pharmaceuticals ABOSTO:NEWBRY -4.62%41 PB Ratio is 2.41 as of Aug. 28, 2026, which is 45% above its 10-year median of 1.66. GuruFocus rates OSTO:NEWBRY with a GF Score™ of 41/100 and a GF Value™ of kr3.20 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 918 Drug Manufacturers companies, Newbury Pharmaceuticals AB ranks worse than 59.48% on this metric.
Newbury Pharmaceuticals AB stock PB Ratio (=2.66) is close to 3-year high of 2.66.
The historical rank and industry rank for Newbury Pharmaceuticals AB's PB Ratio or its related term are showing as below:
OSTO:NEWBRY'
s PB Ratio Range Over the Past 10 Years
Min: 0.89 Med: 1.66 Max: 5.69
Current: 2.41
During the past 5 years, Newbury Pharmaceuticals AB's highest PB Ratio was 5.69. The lowest was 0.89. And the median was 1.66.
OSTO:NEWBRY's PB Ratio is ranked worse than 59.48% of 918
companies
in the Drug Manufacturers industry
Industry Median: 1.97
vs OSTO:NEWBRY: 2.41
During the past 12 months, Newbury Pharmaceuticals AB's average Book Value Per Share Growth Rate was -44.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -26.40% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Newbury Pharmaceuticals AB was -4.50% per year. The lowest was -26.40% per year. And the median was -15.45% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Newbury Pharmaceuticals AB PB Ratio Related Terms
Newbury Pharmaceuticals AB PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:NEWBRY vs ZTS, UTHR, VTRS: PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newbury Pharmaceuticals AB PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Newbury Pharmaceuticals AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Newbury Pharmaceuticals AB (OSTO:NEWBRY) has a PB Ratio of 2.41 as of Aug. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Newbury Pharmaceuticals AB and its competitors. This is 45% above median its historical median of 1.66. Over the past decade, Newbury Pharmaceuticals AB's PB Ratio has ranged from 0.89 to 5.69. According to the industry distribution chart, Newbury Pharmaceuticals AB ranks #546 out of 918 companies in the Drug Manufacturers industry, placing it in the top 59.5%.
Is Newbury Pharmaceuticals AB's PB Ratio too high?
Newbury Pharmaceuticals AB's current PB Ratio of 2.41 is 45% above median its 10-year median of 1.66. Over the past 10 years, this metric has ranged from a low of 0.89 to a high of 5.69. The Drug Manufacturers industry median PB Ratio is 1.97. Newbury Pharmaceuticals AB's value of 2.41 is 22.3% above this industry median. Based on the distribution chart, Newbury Pharmaceuticals AB ranks #546 out of 918 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 41/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Newbury Pharmaceuticals AB ranks #546 out of 918 companies for PB Ratio. This places Newbury Pharmaceuticals AB in the lower half of its industry. The industry median PB Ratio is 1.97. Newbury Pharmaceuticals AB's value of 2.41 is 22.3% above this benchmark. Historically, Newbury Pharmaceuticals AB's own PB Ratio has ranged from 0.89 to 5.69 over the past decade. While the company's 10-year median is 1.66 vs. the industry median of 1.97, Newbury Pharmaceuticals AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.97, based on 918 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Newbury Pharmaceuticals AB's current PB Ratio of 2.41 is 22.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Newbury Pharmaceuticals AB and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newbury Pharmaceuticals AB's current PB Ratio is 2.41, which is 45% above median its own 10-year median of 1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB (OSTO:NEWBRY) is currently considered Modestly Undervalued. The stock's GF Value™ is kr3.20, compared to a current price of kr2.48 — trading 22.5% below its estimated fair value. The current PB Ratio is 2.41, which is 45% above median its 10-year median of 1.66 and 22.3% above the Drug Manufacturers industry median of 1.97. Newbury Pharmaceuticals AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (OSTO:NEWBRY), the current PB Ratio is 2.41 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newbury Pharmaceuticals AB (OSTO:NEWBRY) Overvalued in 2026?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued.
The current stock price of kr2.48 is trading 22.5% below its estimated GF Value™ of kr3.20.
GuruFocus considers Newbury Pharmaceuticals AB to be Modestly Undervalued.
Key valuation signals for OSTO:NEWBRY:
PB Ratio: 2.41 (45% above median its 10-year median of 1.66)
GF Value™: kr3.20 vs. price of kr2.48 (22.5% below fair value)
Industry Position: 22.3% above the Drug Manufacturers median (#546 of 918)
No single metric tells the full story. See the OSTO:NEWBRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
41GF Score
Get the complete analysis for OSTO:NEWBRY
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NEWBRY has been successfully added to your 
